ArticleACS applied materials & interfaces2025
Targeted Delivery of AGO-2 to Myocardial Mitochondria via Functionalized Nanoparticles Attenuates Oxidative Stress in Diabetic Cardiomyopathy.
Article in ACS applied materials & interfaces, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Nanoparticle-Based Targeted Drug-Delivery Systems for Cardiomyopathy: Mechanisms and Therapeutic Advances.Molecules (Basel, Switzerland) · 2026Review
- Nanomedicine in Cardiovascular Inflammation: Novel Diagnostic and Therapeutic Strategies.Journal of personalized medicine · 2026Review
- Advances in the application of nanoparticles for the diagnosis and treatment of diabetic cardiomyopathy.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mitochondrial dysfunction is a hallmark of early diabetes. Previous studies suggest that Argonaute-2 (AGO-2) supplementation enhances mitochondrial gene expression and improves cellular stability. Here, we investigated AGO-2 expression during diabetic myocardial injury and designed a multifunctional nanocarrier to selectively deliver AGO-2 to cardiac mitochondria, aiming to restore mitochondrial homeostasis and mitigate oxidative stress. We employed an extremely small iron oxide (ESIO) nanoparticle core functionalized with cardiac-homing peptide (CHP) and the mitochondrial-targeting peptide SS-31 to construct a targeted platform, denoted ESIO-SS-31-CHP (ESC). AGO-2 was stably incorporated via phenylboronic acid by B-N binding, yielding ESC-AGO-2. Structural and functional characterizations demonstrated efficient targeting and carrier stability. In diabetic mice, AGO-2 localization in mitochondria was downregulated at 4 weeks and exhibited impaired mitochondrial translocation. ESC-AGO-2 effectively localized to mitochondria in vitro and in vivo, leading to improved mitochondrial performance, reduced oxidative damage, and attenuated inflammatory responses. These findings highlight AGO-2 as a potential biomarker for early diabetes and introduce ESC-AGO-2 as a promising nanomedicine strategy for precision intervention at the onset of diabetic cardiomyopathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.